Document Detail


Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report.
MedLine Citation:
PMID:  11463808     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A newly approved oral fluoropyrimidine, TS-1, is a dihydropyrimide dehydrogenase (DPD)-inhibiting fluoropyrimidine (DIF) drug. We describe a case of interstitial pneumonia probably caused by TS-1. A peripheral blood lymphocytes stimulating test (DLST) with TS-1 demonstrated a substantial positive reaction. So far only three cases of TS-1-induced interstitial pneumonia have been reported but the relationship between interstitial pneumonia and TS-1 was demonstrated only in this case. Considering that interstitial pneumonia has also been reported with 5-FU, it is necessary in the future to clarify which component of this drug is directly related to interstitial pneumonia.
Authors:
E Kurakawa; I Kasuga; S Ishizuka; T Yoshida; A Kunisawa; K Minemura; K Utsumi; K Ohyashiki
Related Documents :
12781398 - Cervical cerclage in delayed interval delivery in a multifetal pregnancy: a review of s...
20605258 - Long-term follow-up study of clear cell papulosis.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Japanese journal of clinical oncology     Volume:  31     ISSN:  0368-2811     ISO Abbreviation:  Jpn. J. Clin. Oncol.     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-07-20     Completed Date:  2001-08-09     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0313225     Medline TA:  Jpn J Clin Oncol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  284-6     Citation Subset:  IM    
Affiliation:
First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy
Aged
Antimetabolites, Antineoplastic / adverse effects*
Drug Combinations
Humans
Lung Diseases, Interstitial / chemically induced*
Male
Oxonic Acid / adverse effects*
Pyridines / adverse effects*
Stomach Neoplasms / drug therapy
Tegafur / adverse effects*
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Drug Combinations; 0/Pyridines; 150863-82-4/S 1 (combination); 17902-23-7/Tegafur; 937-13-3/Oxonic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High dose rate interstitial brachytherapy in soft tissue sarcoma: technical aspects and results.
Next Document:  A nested variant of transitional cell carcinoma of the urinary bladder: a case report.